Alvina D. Chu

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

John C. Byrd, Jennifer R. Brown, Susan O’Brien et al. · New England Journal of Medicine · 2014 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 543 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson et al. · JAMA Dermatology · 2021 · 485 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller et al. · The Lancet · 2021 · 389 citations

Medicine, Dermatology, Pediatrics +16

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Susan O’Brien, Richard R. Furman, Steven Coutré et al. · Blood · 2018 · 387 citations · Full text

Medicine, Oncology, Pharmacology +13